202 related articles for article (PubMed ID: 11957197)
1. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor.
Cottle TE; Fier CJ; Donadieu J; Kinsey SE
Semin Hematol; 2002 Apr; 39(2):134-40. PubMed ID: 11957197
[TBL] [Abstract][Full Text] [Related]
2. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry.
Dale DC; Cottle TE; Fier CJ; Bolyard AA; Bonilla MA; Boxer LA; Cham B; Freedman MH; Kannourakis G; Kinsey SE; Davis R; Scarlata D; Schwinzer B; Zeidler C; Welte K
Am J Hematol; 2003 Feb; 72(2):82-93. PubMed ID: 12555210
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology and treatment of severe chronic neutropenia.
Welte K; Dale D
Ann Hematol; 1996 Apr; 72(4):158-65. PubMed ID: 8624368
[TBL] [Abstract][Full Text] [Related]
4. High incidence of significant bone loss in patients with severe congenital neutropenia (Kostmann's syndrome).
Yakisan E; Schirg E; Zeidler C; Bishop NJ; Reiter A; Hirt A; Riehm H; Welte K
J Pediatr; 1997 Oct; 131(4):592-7. PubMed ID: 9386665
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias.
Bonilla MA; Dale D; Zeidler C; Last L; Reiter A; Ruggeiro M; Davis M; Koci B; Hammond W; Gillio A; Welte K
Br J Haematol; 1994 Dec; 88(4):723-30. PubMed ID: 7529539
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human granulocyte-colony-stimulating factor in the treatment of patients with neutropenia.
Boxer LA; Hutchinson R; Emerson S
Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S39-46. PubMed ID: 1370264
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.
Dale DC; Bonilla MA; Davis MW; Nakanishi AM; Hammond WP; Kurtzberg J; Wang W; Jakubowski A; Winton E; Lalezari P
Blood; 1993 May; 81(10):2496-502. PubMed ID: 8490166
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
[TBL] [Abstract][Full Text] [Related]
9. Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.
Frampton JE; Lee CR; Faulds D
Drugs; 1994 Nov; 48(5):731-60. PubMed ID: 7530630
[TBL] [Abstract][Full Text] [Related]
10. Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor.
Dale DC; Bolyard AA; Shannon JA; Connelly JA; Link DC; Bonilla MA; Newburger PE
Blood Adv; 2022 Jul; 6(13):3861-3869. PubMed ID: 35476051
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of point mutations in the cytoplasmic domain of the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia.
Tidow N; Pilz C; Teichmann B; Müller-Brechlin A; Germeshausen M; Kasper B; Rauprich P; Sykora KW; Welte K
Blood; 1997 Apr; 89(7):2369-75. PubMed ID: 9116280
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of chronic severe neutropenia with weekly recombinant granulocyte-colony stimulating factor.
Fine KD; Byrd TD; Stone MJ
Br J Haematol; 1997 Apr; 97(1):175-8. PubMed ID: 9136962
[TBL] [Abstract][Full Text] [Related]
13. Severe chronic neutropenia in Chinese children in Hong Kong.
Leung TF; Li CK; Kwok KL; Chik KW; Shing MM; Yuen PM
J Paediatr Child Health; 2001 Apr; 37(2):137-41. PubMed ID: 11328467
[TBL] [Abstract][Full Text] [Related]
14. The clinical utility of granulocyte colony-stimulating factor: early achievements and future promise.
Morstyn G; Foote M; Perkins D; Vincent M
Stem Cells; 1994; 12 Suppl 1():213-27; discussion 227-8. PubMed ID: 7535147
[TBL] [Abstract][Full Text] [Related]
15. Biopharmaceutical drug development: Filgrastim (r-metHuG-CSF) use in patients with HIV infection.
Foote M; Welch W
J Hematother Stem Cell Res; 1999; 8 Suppl 1():S3-8. PubMed ID: 10596029
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
Sagara Y; Sato K; Fukuma E; Higaki K; Mizutani M; Osaki A; Takano T; Tokuda Y; Ohno S; Masuda N; Suzuki M; Saeki T
Jpn J Clin Oncol; 2013 Sep; 43(9):865-73. PubMed ID: 23858037
[TBL] [Abstract][Full Text] [Related]
17. Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry.
Beaupain B; Leblanc T; Reman O; Hermine O; Vannier JP; Suarez F; Lutz P; Bordigoni P; Jourdain A; Schoenvald M; Ouachee M; François S; Kohser F; Jardin F; Devouassoux G; Bertrand Y; Nove-Josserand R; Donadieu J;
Pediatr Blood Cancer; 2009 Dec; 53(6):1068-73. PubMed ID: 19618456
[TBL] [Abstract][Full Text] [Related]
18. Complication of rapidly progressive glomerulonephritis in severe congenital neutropenia treated with long-term granulocyte colony-stimulating factor (filgrastim).
Sotomatsu M; Kanazawa T; Ogawa C; Watanabe T; Morikawa A
Br J Haematol; 2000 Jul; 110(1):234-5. PubMed ID: 10931006
[No Abstract] [Full Text] [Related]
19. Severe chronic neutropenia: pathophysiology and therapy.
Welte K; Boxer LA
Semin Hematol; 1997 Oct; 34(4):267-78. PubMed ID: 9347577
[TBL] [Abstract][Full Text] [Related]
20. Effects of recombinant human granulocyte colony-stimulating factor (filgrastim) on ECG parameters in neutropenic patients: a single-centre, prospective study.
Guneysel O; Onur OE; Denizbasi A
Clin Drug Investig; 2009; 29(8):551-5. PubMed ID: 19591516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
